Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SGMT 
Sagimet Biosciences Inc. Series A Common Stock (SGMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SGMT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.44
1 Year Target Price $23.44
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 141.82% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 245.86M USD | Price to earnings Ratio - | 1Y Target Price 23.44 |
Price to earnings Ratio - | 1Y Target Price 23.44 | ||
Volume (30-day avg) 7 | Beta 3.41 | 52 Weeks Range 1.73 - 11.41 | Updated Date 08/29/2025 |
52 Weeks Range 1.73 - 11.41 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.86 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.88 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.61% | Return on Equity (TTM) -37.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 120608288 | Price to Sales(TTM) 52.5 |
Enterprise Value 120608288 | Price to Sales(TTM) 52.5 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -1.93 | Shares Outstanding 31001100 | Shares Floating 22626577 |
Shares Outstanding 31001100 | Shares Floating 22626577 | ||
Percent Insiders 9.81 | Percent Institutions 29.21 |
Upturn AI SWOT
Sagimet Biosciences Inc. Series A Common Stock
Company Overview
History and Background
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases with unmet medical needs, primarily non-alcoholic steatohepatitis (NASH) and cancers. The company was founded to target fatty acid synthase (FASN), an enzyme involved in the de novo synthesis of fatty acids.
Core Business Areas
- NASH (Non-Alcoholic Steatohepatitis): Developing Denifanstat (TVB-2640) as a potential treatment for NASH, a liver disease characterized by fat accumulation and inflammation.
- Oncology: Exploring the use of Denifanstat and other FASN inhibitors in various cancer types.
Leadership and Structure
The leadership team consists of experienced biopharmaceutical executives. The company has a board of directors overseeing its operations and strategic direction.
Top Products and Market Share
Key Offerings
- Denifanstat (TVB-2640) for NASH: Denifanstat, the lead drug candidate, is an oral, selective fatty acid synthase (FASN) inhibitor. Currently in Phase 2b clinical trial for NASH. The NASH market is expected to grow substantially, with various competitors including Madrigal Pharmaceuticals and Viking Therapeutics. Market share is currently 0 as the product is pre-market.
- Denifanstat for Oncology: Exploring Denifanstat's potential in various cancer indications. Competitors depend on the specific cancer target. Market share is currently 0 as the product is pre-market.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on NASH and oncology, is highly competitive and innovative. NASH represents a large unmet medical need with a growing patient population. Cancer drug development is also a significant area of research and investment.
Positioning
Sagimet is positioned as a clinical-stage company with a focus on FASN inhibition. Its competitive advantage lies in its novel approach to targeting metabolic pathways in liver disease and cancer.
Total Addressable Market (TAM)
The NASH market is estimated to reach $20-$35 billion in the coming years. The oncology market is significantly larger. Sagimet aims to capture a portion of these markets through its drug development programs.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (FASN inhibition)
- Promising clinical trial results for Denifanstat in NASH
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single lead drug candidate
- High cash burn rate typical of clinical-stage companies
- Clinical trial risk and regulatory hurdles
- Limited commercialization experience
Opportunities
- Positive clinical trial outcomes leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of Denifanstat's use to other indications
- Acquisition by a larger pharmaceutical company
Threats
- Failure to achieve positive clinical trial results
- Regulatory setbacks
- Competition from other NASH and oncology drugs
- Patent challenges
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- Madrigal Pharmaceuticals (MDGL)
- Viking Therapeutics (VKTX)
- Akero Therapeutics (AKRO)
- 89bio, Inc. (ETNB)
Competitive Landscape
Sagimet competes with other companies developing NASH and oncology drugs. Its competitive advantage depends on the efficacy and safety profile of Denifanstat compared to existing and investigational treatments. Note: all products are pre-market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by progress in clinical trials and expansion of the pipeline.
Future Projections: Future growth depends on the success of Denifanstat's clinical trials and potential regulatory approval. Analyst estimates vary based on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include the advancement of Denifanstat through clinical trials, exploration of new indications, and fundraising activities.
Summary
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on NASH and oncology with a novel FASN inhibition approach. The success of the company hinges on positive results from its ongoing clinical trials of Denifanstat. They face competition from larger and more established companies. Sagimet will need to focus on effective execution of its clinical development plan to achieve its goals and maintain a healthy cash runway.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sagimet Biosciences Inc. Series A Common Stock
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2023-07-14 | CEO, President & Director Mr. David A. Happel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.sagimet.com |
Full time employees 14 | Website https://www.sagimet.com | ||
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.